Company
Indivior PLC
LON: INDV
The world leader in addiction treatment with 20 years of experience and a unique, patient-focused approach.We didn’t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They’re often unaware of their treatment options, have limited access to treatment, or simply don’t seek it out because they’re afraid of being stigmatized.
42 stories
Indivior swoops for US addiction specialist in US$200mln deal
Opiant, the business being acquired, is developing drugs that reverse overdose and tackle addiction
Indivior considers US listing as sales soar
The company forecast net revenue in the range of US$840mln-US$900mln for 2022, reflecting strong growth in the addiction treatment Sublocade
Archive
Will Indivior get back to black on Wednesday?
Indivior will be among the notable names for Wednesday, but really the spotlight will be on UK inflation numbers.
Indivior hails results from buprenorphine-fentanyl interaction study
The majority of opioid-related overdose deaths in the US are the result of synthetic opioids such as fentanyl
Indivior’s largest shareholder sells chunk of shares
Scopia Capital Management will remain the top shareholder in the pharma group
Indivior raises 2021 revenue and profit estimates
Adjusted pre-tax income will be significantly above original guidance
Indivior shareholders told to rebel against jailed ex-CEO's bonus
According to ISS, Thaxter left the company with unvested bonus shares worth more than US$1.5mln currently.
Indivior in red after legal settlements take toll
Losses for the year were US$173mln with a US$14mln deficit in the final three months
Indivior raises profit target after resilient showing from Suboxone
General overhead costs are also expected to come in below the US$470mln-US$480mln range guided previously
Indivior says £1bn Reckitt Benckiser claim is without merit
Indivior added that as yet it has not been served with a claim
Indivior facing £1bn claim from former parent Reckitt Benckiser
Indivior has been dogged by lawsuits over its opioid dependency treatment suboxone ever since the demerger.
Indivior receives US$600mln settlement approval from US federal court
The pharma company reached an agreement in July for the lawsuit over its anti-addiction treatment Suboxone
Indivior ex-CEO sentenced to jail in the US over misleading safety claims
The US state attorney said Shaun Thaxter had “failed to prevent efforts to build profits through misleading safety claims, which led to millions of dollars in ill-gotten gains for Indivior”
Indivior cutting jobs as part of product refocus
Within the pipeline, the priorities include a potential treatment of alcohol use disorder
Indivior soars as it reaches settlement with US authorities over Suboxone lawsuit
The drugmaker has agreed to pay US$600mln over seven years and has pleaded guilty to one count of making a false statement relating to health care matters
Jefferies on the fence over Indivior ahead of September court date
The market is pricing only a 20% chance that the best case, a settlement before the court date, according to Jefferies.
Indivior looking at appeal of final decision by US patent office on Suboxone copycat
The US authorities ruled that Dr. Reddy’s, the producer of the generic version of the drug, demonstrated that certain claims are unpatentable
Indivior throws out guidance as coronavirus dents patient numbers
The pharmaceutical firm said the pandemic had resulted in a “meaningful decline” in enrolments for its SUBLOCADE and PERSERIS injections and the market share strength of its SUBOXONE opioid dependency treatment
Indivior expects to swing to 2020 loss as Suboxone sales keep falling
Revenues fell 22% last year, primarily due to the erosion of market share for its historical leading product, Suboxone Film for opioid addiction
Indivior long-acting drug for opioid addiction builds on early promise
Researchers confirmed that users of Sublocade reported better health, higher medication satisfaction, increased employment and decreased healthcare utilisation compared with those using a placebo with no medicinal benefit
Indivior’s anti-opioid addiction drug struggles against generic competitors
In the three months to 30 September, total net revenue decreased 19% to US$199mln
Indivior’s Suboxone drives up expectations once again
The company expects 2019 group net revenue to be up to US$790mln, compared to previous forecasts of up to US$720mln